Daisy Lab’s Global Buyout - A Sign of Things to Come for Kiwi Biotech?

New Zealand’s cow-free dairy science has attracted an overseas buyer and raised a familiar question about where our best ideas go to grow. British biotechnology group Mycofeast has acquired Auckland’s Daisy Lab's lab for an undisclosed sum, bringing its precision fermentation work into an international ingredients business.

For consumers, the potential is another step towards nutrition products made with dairy-identical proteins produced without cows. For New Zealand, the question is how much of that future we can build here.

Daisy Lab’s immediate focus is lactoferrin, a high-value milk protein. As reported, the acquisition brings no associated layoffs, while the founders take roles within the wider group. The next 12 months are expected to involve further scale-up, regulatory filings, customer trials and transferring the production process into Mycofeast’s manufacturing operation. There is still work between the science and the shelf.

Mycofeast brings infrastructure that would take a small company considerable time and money to assemble. Headquartered in Oxford, it has a synthetic biology hub in California and a manufacturing operation in Poland, where it is converting a former Heineken brewery into a biotechnology production platform. Its Evolutia Bio subsidiary contributes strain engineering expertise, connecting the development of microorganisms with the demands of industrial production.

Could this be a portent for Kiwi biotech? Quite possibly. The commercial gap it exposes has been recognised for years. BioTechNZ’s 2020 sector study identified access to capital as the most significant constraint on both research and commercialisation, a finding the organisation highlighted again in 2022. Daisy Lab gives that longstanding concern a fresh, practical example: promising science needs enough financial runway to become a dependable, saleable ingredient.

Our reading is more young companies could follow a similar path if overseas groups can offer funding, facilities and customers together. That can benefit founders and keep development moving. It also makes the terms of each deal important: where the scientists work, where production expands, and where future earnings accumulate. With Daisy Lab’s purchase price undisclosed, there is no basis yet to judge the financial return to its backers.

New Zealand has good reason to welcome international demand for its biotechnology. The larger ambition should be to turn that demand into lasting capability here, too. Daisy Lab’s acquisition is an encouraging vote of confidence in Kiwi science and a timely prompt to ask whether we are investing enough in what comes after the discovery.

ENDS: